Butylnitrone containing compositons for inhibition of cancer development
CA 2404291 A1 · Owner: Nakae, Dai · Inventors: Floyd, Robert A.; Kotake, Yashige; Hensley, Kenneth
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
PBN (.alpha.-phenyl-tert-butylnitrone) and its derivatives nitrone-based free radical traps, significantly reduce preneoplastic nodule development as well as inhibit hepatocellular carcinoma (HCC) formation at very low levels. The involvement of reactive oxygen speices (ROS) in cancer development has been strongly implicated for many years. The involvement of ROS has been strongly implicated in cancer development in a model system where feeding a choline deficiency (CD) diet to rats leads to hepatocellular carcinoma (HCC) development. Administering PBN in the drinking water inhibits HCC formation. Preneoplatic nodule growth in the liver is significantly suppressed by administering …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 28, 2001. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended March 28, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 28, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.